ARTEMIN Promotes De Novo Angiogenesis in ER Negative Mammary Carcinoma through Activation of TWIST1-VEGF-A Signalling

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Banerjee, Arindam ^a   Wu, Zheng Sheng ^b,c,d   Qian, Peng Xu ^b   Kang, Jian ^a   Liu, Dong Xu ^a   Zhu, Tao ^b   Lobie, Peter E ^e  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BEVACIZUMAB; CD31 ANTIGEN; CD34 ANTIGEN; PROTEIN KINASE B; PROTEIN TWIST 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVATION; ESTROGEN RECEPTOR NEGATIVE MAMMARY CARCINOMA; FEMALE; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; PARACRINE SIGNALING; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TWIST TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869840129     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050098     Document Type: Article

References (38)

1. Schneider BP, Miller KD, (2005) Angiogenesis of Breast Cancer. Journal of Clinical Oncology 23: 1782-1790.
2. Loges S, Mazzone M, Hohensinner P, Carmeliet P, (2009) Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15: 167-170.
3. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
4. Kang J, Perry JK, Pandey V, Fielder GC, Mei B, et al. (2009) Artemin is oncogenic for human mammary carcinoma cells. Oncogene 28: 2034-2045.
5. Ceyhan GO, Giese NA, Erkan M, Kerscher AG, Wente MN, et al. (2006) The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann Surg 244: 274-281.
6. Pandey V, Qian PX, Kang J, Perry JK, Mitchell MD, et al. (2010) Artemin stimulates oncogenicity and invasiveness of human endometrial carcinoma cells. Endocrinology 151: 909-920.
7. Tang J-Z, Kong X-J, Kang J, Fielder GC, Steiner M, et al. (2010) Artemin-Stimulated Progression of Human Non Small Cell Lung Carcinoma Is Mediated by BCL2. Molecular Cancer Therapeutics 9: 1697-1708.
8. Banerjee A, Wu ZS, Qian P, Kang J, Pandey V, et al. (2011) ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma. Breast Cancer Res 13: R112.
9. Pandey V, Jung Y, Kang J, Steiner M, Qian PX, et al. (2010) Artemin Reduces Sensitivity to Doxorubicin and Paclitaxel in Endometrial Carcinoma Cells through Specific Regulation of CD24. Transl Oncol 3: 218-229.
10. Kang J, Qian PX, Pandey V, Perry JK, Miller LD, et al. (2010) Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma. Oncogene 29: 3228-3240.
11. Romon R, Adriaenssens E, Lagadec C, Germain E, Hondermarck H, et al. (2010) Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways. Mol Cancer 9: 157.
12. Tsutsui S, Matsuyama A, Yamamoto M, Takeuchi H, Oshiro Y, et al. (2010) The Akt expression correlates with the VEGF-A and-C expression as well as the microvessel and lymphatic vessel density in breast cancer. Oncol Rep 23: 621-630.
13. Jiang BH, Liu LZ, (2008) PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 1784: 150-158.
14. Mironchik Y, Winnard PT Jr, Vesuna F, Kato Y, Wildes F, et al. (2005) Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res 65: 10801-10809.
15. Hu L, Roth JM, Brooks P, Ibrahim S, Karpatkin S, (2008) Twist is required for thrombin-induced tumor angiogenesis and growth. Cancer Res 68: 4296-4302.
16. Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, et al. (2011) Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res 13: R59.
17. Brunet-Dunand SE, Vouyovitch C, Araneda S, Pandey V, Vidal LJ, et al. (2009) Autocrine human growth hormone promotes tumor angiogenesis in mammary carcinoma. Endocrinology 150: 1341-1352.
18. Airaksinen MS, Saarma M, (2002) The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3: 383-394.
19. Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE, et al. (2009) ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther 8: 1045-1054.
20. Skinner HD, Zheng JZ, Fang J, Agani F, Jiang BH, (2004) Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem 279: 45643-45651.
21. Loges S, Schmidt T, Carmeliet P, (2010) Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 1: 12-25.
22. El Agouza IM, Eissa SS, El Houseini MM, El-Nashar DE, Abd El Hameed OM, (2011) Taurine: a novel tumor marker for enhanced detection of breast cancer among female patients. Angiogenesis 14: 321-330.
23. Giovannini M, Aldrighetti D, Zucchinelli P, Belli C, Villa E, (2010) Antiangiogenic strategies in breast cancer management. Crit Rev Oncol Hematol 76: 13-35.
24. Relf M, LeJeune S, Scott PA, Fox S, Smith K, et al. (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57: 963-969.
25. Cao Y, Liu Q, (2007) Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis. Adv Cancer Res 97: 203-224.
26. Shibuya M, (2008) Vascular endothelial growth factor-dependent and-independent regulation of angiogenesis. BMB Rep 41: 278-286.
27. Eck SM, Hoopes PJ, Petrella BL, Coon CI, Brinckerhoff CE, (2009) Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat 116: 79-90.
28. Bajou K, Lewalle JM, Martinez CR, Soria C, Lu H, et al. (2002) Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expression. Int J Cancer 100: 501-506.
29. Lin Y, Huang R, Chen L, Li S, Shi Q, et al. (2004) Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer 109: 507-515.
30. Zhao Y, Bao Q, Renner A, Camaj P, Eichhorn M, et al. (2011) Cancer stem cells and angiogenesis. Int J Dev Biol 55: 477-482.
31. Toi M, Matsumoto T, Bando H, (2001) Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2: 667-673.
32. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, et al. (2005) VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 201: 1089-1099.
33. Beck B, Driessens G, Goossens S, Youssef KK, Kuchnio A, et al. (2011) A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 478: 399-403.
34. Manders P, Beex LV, Tjan-Heijnen VC, Geurts-Moespot J, Van Tienoven TH, et al. (2002) The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer 87: 772-778.
35. Kannan N, Kang J, Kong X, Tang J, Perry JK, et al. (2010) Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia 12: 1041-1053.
36. Ahmed AR, Griffiths AB, Tilby MT, Westley BR, May FE, (2012) TFF3 is a normal breast epithelial protein and is associated with differentiated phenotype in early breast cancer but predisposes to invasion and metastasis in advanced disease. Am J Pathol 180: 904-916.
37. Boulay A, Breuleux M, Stephan C, Fux C, Brisken C, et al. (2008) The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer. Cancer Res 68: 3743-3751.
38. Bespalov MM, Sidorova YA, Tumova S, Ahonen-Bishopp A, Magalhaes AC, et al. (2011) Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin. J Cell Biol 192: 153-169.